^
Association details:
| Biomarker: | PD-L1 expression + T-cell gene signature |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Published date:
11/11/2020
Excerpt:
Patients in T-cell and MHC I–double-high subgroups showed further improvement in clinical efficacy (40% objective response rate [ORR], 5.26 month median progression-free survival [PFS], and 15.2 month median OS) than other subgroups (table 1).T-cell and MHC I GS were identified as potentially predictive biomarkers of response to tislelizumab monotherapy in PD-L1+ UC in this retrospective analysis.
Trial ID:
